Clinical Trial Update: A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 open-label study of ENMD-2076 in patients with advanced fibrolamellar hepatocellular carcinoma and advanced hepatocellular carcinoma completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• ENMD-2076 (ENMD-2076)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-04-18